About Us
USBIOTICS® realizes the greatest threat to America in the 21st century are biological weapons and over 18 countries possess this power. The US Homeland needs novel countermeasures to avoid this serious national security threat and Anti-Chemical/Biological Warfare Agents (Anti-CBW Agents) can provide this protection.
USBIOTICS® Board of Directors
Dr. P.K. Richter, Founder/CEO and Chief Patent Counsel of USBIOTICS® Under his strategic direction, the organization is poised to expand its role as a key player in the development of essential Homeland Security projects, including Anti-Chemical/Biological Warfare Agents (Anti-CBW Agents).
C.J. Eschenbach, Ph.D., President and Director of Laboratory Operations Dr. Eschenbach leads the R&D, laboratory operations, and Quality Assurance teams. Under Eschenbach’s leadership, USBIOTICS® is moving forward in it’s goal of developing effective countermeasure bioweapon technology.
S.G. Taylor M.D., Chief Medical Scientist. Dr. Taylor has extensive experience in stepping up USBIOTICS® genetic testing, molecular diagnostics, and clinical laboratory operations. Taylor has successfully built and run high-volume clinical laboratories to hospital health systems.
D.D. Emmons, J.D., Tech Transfer Director of USBIOTICS® Emmons is actively involved in building relationships with our partners.
Research
Currently under research: Multi generation Cephalosporins and Vancomycin pro-drugs
Discovery
Pro-drug delivery systems, including antibiotic analogs based on penicillin G, ceftriaxone, and ampicillins.
Analysis
Derivatives including Clindamycin analogs for C. difficile bacteria resistance
Testing
ESBL strains resistant to non-beta-lactam antibiotics and pro-drugs effective against this resistance.